Company intelligence

Vaderis Therapeutics

BiotechBasel, SwitzerlandWebsite ↗See connections →

Is this your company? Get featured or correct your listing →

Suggest a correction

Recent changes

  1. Aug 11, 2026Raised $152.5M Series B PR Newswire
  2. Aug 11, 2026New investor: Goldman Sachs Alternatives PR Newswire
  3. Aug 11, 2026New investor: TCGX PR Newswire

Funding History

1 event · sources dated per row
DateEventAmountValuationInvestorsSource
Aug 11, 2026Series B$152.5M—
Goldman Sachs AlternativesLeadTCGXLead
Pulse story

Investors

Goldman Sachs AlternativesTCGX

Latest Pulse

  1. Vaderis Raises $152M Series B for Rare Disease TrialVaderis Therapeutics closed an oversubscribed $152.5 million Series B co-led by Goldman Sachs Alternatives and TCGX to fund a global Phase 3 trial of its drug for a rare blood vessel disorder.→

Coverage Timeline

newest first
  1. Aug 11, 2026FUNDINGVaderis Raises $152M Series B for Rare Disease Trial$152.5M Series B→

All Coverage

FUNDING

Vaderis Raises $152M Series B for Rare Disease Trial

Illustration for: Vaderis Raises $152M Series B for Rare Disease Trial
FUNDING$152.5M Series B

Vaderis Raises $152M Series B for Rare Disease Trial

Vaderis Therapeutics closed an oversubscribed $152.5 million Series B co-led by Goldman Sachs Alternatives and TCGX to fund a global Phase 3 trial of its drug for a rare blood vessel disorder.

DEEP DIVE

Related Companies

Same sector
Scribe TherapeuticsAttovia TherapeuticsApnimedIambic TherapeuticsRetension PharmaceuticalsEli Lilly

Vaderis Therapeutics FAQ

Who are Vaderis Therapeutics's investors?

Vaderis Therapeutics's investors include Goldman Sachs Alternatives, TCGX.

Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction